Dr. Godwin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4805 Ne Glisan St
Ste 6n40
Portland, OR 97213Phone+1 503-215-5696Fax+1 217-545-4788- Is this information wrong?
Summary
- Dr. John Godwin is an oncologist in Portland, OR and is affiliated with multiple hospitals in the area, including Providence Milwaukie Hospital, Providence Newberg Medical Center, Providence Portland Medical Center, Providence St. Vincent Medical Center, and Providence Willamette Falls Medical Center. He received his medical degree from University of Alabama School of Medicine and has been in practice 43 years. He specializes in hematologic oncology and is experienced in acute myeloid leukemia and ovarian cancer. He has more than 100 publications and over 500 citings.
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 1983 - 1985
Baylor College of MedicineResidency, Internal Medicine, 1979 - 1983- Baylor College of MedicineInternship, Transitional Year, 1978 - 1979
University of Alabama School of MedicineClass of 1978
Certifications & Licensure
OR State Medical License 2012 - 2025
IL State Medical License 1985 - 2014
AL State Medical License 1979 - 2012
NC State Medical License 1982 - 2012- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACP) American College of Physicians, 2011
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- flt3L in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2000 Jul 01
- S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia Start of enrollment: 2003 Apr 01
- Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2008 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.Algazi, A., Moon, J., Lao, C., Chmielowski, B., Kendra, K., Lewis, K., Gonzalez, R., Kim, K., Godwin, J., Curti, B., Latkovic-Taber, M., Lomeli, S., Gufford, B., Scump...> ;Cancer. 2024 Jan 23
- 52 citationsLisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transpla...Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C Hildebrandt, John E Godwin, Patrick M Reagan, Nina Wagner-Johnston, James Essel...> ;The Lancet. Oncology. 2022 Aug 1
- Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data.Megan Othus, Guillermo Garcia-Manero, John E Godwin, James K Weick, Frederick R Appelbaum, Harry P Erba, Elihu H Estey> ;Haematologica. 2023 Jan 1
- Join now to see all
Journal Articles
- Second Cycle Remission Achievement with 7+3 and Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG TrialsBrent L Wood, Roland B Walter, John E Godwin, James K Weick, Elihu H Estey, Derek L Stirewalt, Frederick R Appelbaum, Nature
Abstracts/Posters
- Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG ReportJohn E. Godwin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particular...John E. Godwin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial DataJohn E. Godwin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
MacroGenics : Flotetuzumab (CD123 X CD3) as Salvage Therapy for PIF and ER AML (Aldoss)December 7th, 2020
The Hunt for a CRISPR Antidote Just Heated UpMay 21st, 2019
Professional Memberships
- Fellow
Hospital Affiliations
Providence Milwaukie HospitalPortland, Oregon
Providence Newberg Medical CenterNewberg, Oregon
Providence Portland Medical CenterPortland, Oregon
Providence St. Vincent Medical CenterPortland, Oregon
Providence Willamette Falls Medical CenterOregon City, Oregon
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
